<!DOCTYPE html><html><head><link rel="stylesheet" href="../displacy.css"></head><body><section class="edgaug_item7" id="edgaug_item7_id">ITEM 7 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt">The following discussion should
be read in conjunction with our audited consolidated financial statements and notes thereto for <mark data-entity="date">the fiscal year ended September
30, 2019</mark>, included elsewhere in <mark data-entity="org">this Annual Report</mark> on Form 10-K.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Financial
Highlights</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During <mark data-entity="date">fiscal
2019</mark>, we make significant progress in the advancement of clinical studies for <mark data-entity="org">ANAVEX</mark>®2-73, including commencement of a Phase
<mark data-entity="cardinal">2b/3</mark> Alzheimer’s disease trial in <mark data-entity="date">August 2018</mark>, a Phase 2 Parkinson’s disease dementia trial in <mark data-entity="date">October 2018</mark>, and a
multi-regional Phase 2 clinical program for the treatment of Rett syndrome in <mark data-entity="date">March 2019</mark>. As a result, our operating expenses
for fiscal 2019 increased to <mark data-entity="money">$29.1 million</mark>, from <mark data-entity="money">$19.3 million</mark> in <mark data-entity="date">fiscal 2018</mark>. The increase is attributable to an increase in
research and development expenses of <mark data-entity="money">$9.0 million</mark> in 2019, from <mark data-entity="money">$13.3 million</mark> in <mark data-entity="date">fiscal 2018</mark>.to <mark data-entity="money">$22.3 million</mark> in fiscal 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During <mark data-entity="date">fiscal
2019</mark>, we utilized <mark data-entity="money">$18.5 million</mark> to fund our operations, compared to <mark data-entity="money">$12.6 million</mark> during <mark data-entity="date">fiscal 2018</mark>. Our cash position decreased
only slightly by <mark data-entity="money">$0.7 million</mark> during fiscal 2019, to <mark data-entity="money">$22.2 million</mark>. The majority of our operations were financed through the issuance
of shares of common stock under the purchase agreements by and between the <mark data-entity="org">Company</mark> and <mark data-entity="org">Lincoln Park Capital Fund</mark>, <mark data-entity="org">LLC</mark> (“<mark data-entity="work_of_art">Lincoln
Park</mark>”).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We expect
our research and development expenses will continue to increase as we advance our <mark data-entity="org">ANAVEX</mark>®sup>®</sup>2-73 clinical studies,
including adding extension studies to allow us to continue to gather longer term data, and adding additional staffing to advance
the clinical studies currently underway. We will continue to target potential research partners to further advance our pipeline
compounds. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Net loss
for fiscal 2019 was <mark data-entity="money">$26.3 million</mark>, or $0.54 per share, as compared to $17.3 million, or $0.39 per share in <mark data-entity="date">fiscal 2018</mark>.</font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 32; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Results
of Operations</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Revenue</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; font-style: normal">We
are in the development stage and have not earned any revenues since our inception in <mark data-entity="date">2004</mark>. We do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; font-style: normal"><b> </b></font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; font-style: normal"><b>Year
ended September 30, 2019 compared to <mark data-entity="date">year ended September 30, 2018</mark></b></font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Operating
Expenses</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Total operating
expenses for <mark data-entity="date">the year ended September 30, 2019</mark> were <mark data-entity="money">$29.1 million</mark>, compared to <mark data-entity="money">$19.3 million</mark> in <mark data-entity="date">fiscal 2018</mark>. which was an increase
of <mark data-entity="money">approximately $9.8 million</mark> from <mark data-entity="date">fiscal 2018</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Research
and development expenses for fiscal 2019 were <mark data-entity="money">$22.3 million</mark>  as compared to <mark data-entity="money">$13.3 million</mark> <mark data-entity="date">fiscal 2018</mark>. an increase of <mark data-entity="money">$9.0 million</mark> 
During fiscal 2019, research and development expenses included <mark data-entity="money">approximately $0.4 million</mark> spent in connection with the Phase 2a
extension trial for Alzheimer’s Disease, compared to <mark data-entity="money">approximately $0.4 million</mark> in <mark data-entity="date">fiscal 2018</mark>. In addition, in <mark data-entity="date">August 2018</mark>,
we initiated a Phase
<mark data-entity="cardinal">2b/3</mark> clinical trial in Alzheimer’s Disease and during fiscal 2019 research and development expenses
included <mark data-entity="money">approximately $6.2 million</mark> spent in connection with this trial, as compared to <mark data-entity="money">approximately $2.4 million</mark> in <mark data-entity="date">fiscal 2018</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">In <mark data-entity="date">October
2018</mark>, we initiated a Phase 2 clinical trial for Parkinson’s Disease Dementia and during fiscal 2019 research and development
expenses included <mark data-entity="money">approximately $3.3 million</mark> spent in connection with this trial, as compared to <mark data-entity="money">approximately $0.9 million</mark> in <mark data-entity="date">fiscal 2018</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Additionally,
research and development expenses during fiscal 2019 included <mark data-entity="money">approximately $3.0 million</mark> in connection with the Phase 2 clinical
studies for the treatment of Rett syndrome, as compared to <mark data-entity="money">approximately $0.6 million</mark> in <mark data-entity="date">fiscal 2018</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During <mark data-entity="date">fiscal
2019</mark>, we spent <mark data-entity="money">approximately $2.3 million</mark> on preclinical development activities for <mark data-entity="org">ANAVEX</mark>®2-73 and <mark data-entity="org">ANAVEX</mark>®<mark data-entity="date">3-71</mark>, as compared
to <mark data-entity="money">approximately $3.9 million</mark> in <mark data-entity="date">fiscal 2018</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The remainder
of research and development expenses consisted primarily of personnel costs, including non-cash stock option compensation charges
of <mark data-entity="money">$3.2 million</mark>, as compared to <mark data-entity="money">$2.8 million</mark> in <mark data-entity="date">fiscal 2018</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">During <mark data-entity="date">fiscal
2019</mark>,our general and administrative expenses were <mark data-entity="money">$6.8 million</mark> as compared to <mark data-entity="money">$6.0 million</mark> in <mark data-entity="date">fiscal 2018</mark>. an increase of <mark data-entity="money">$0.8
million</mark>, primarily related to salaries and wages, including stock-option compensation charges associated with an increase in staffing
and personnel.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><i>Other
income </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The net
amount of other income for <mark data-entity="date">the year ended September 30, 2019</mark> was <mark data-entity="money">$2.9 million</mark> as compared to <mark data-entity="money">$2.2 million</mark> for the comparable period
of <mark data-entity="date">fiscal 2018</mark>. During fiscal 2019, we recorded <mark data-entity="money">$2.5 million</mark> in the research and development incentive income, including the Australian
research and development incentive credit administered through <mark data-entity="org">the Australian Tax Office</mark>, and <mark data-entity="org">the New York City Biotechnology
Tax Credit</mark> from <mark data-entity="gpe">the City of New York</mark>, in connection with fiscal 2019 eligible expenditures. In comparison, research and development
incentive income for <mark data-entity="date">fiscal 2018</mark>.was <mark data-entity="money">$1.8 million</mark> in connection with <mark data-entity="date">fiscal 2018</mark>.eligible expenditures.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We received
<mark data-entity="money">$0.3 million</mark> in connection with a financial grant from the <mark data-entity="org">Rettsyndrome.org</mark> foundation, which was awarded to cover some of the
costs of the Phase 2 clinical trial of <mark data-entity="org">ANAVEX</mark>®sup>®</sup>2-73 for the treatment of Rett syndrome, as compared to <mark data-entity="money">$0.15 million</mark>
received during <mark data-entity="date">fiscal 2018</mark>.in connection with the same award, which is being received in <mark data-entity="date">quarterly</mark> instalments over a <mark data-entity="date">two year</mark>
period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 33; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Net loss
for fiscal 2019 was <mark data-entity="money">$26.3 million</mark>, or $0.54 per share, compared to a net loss of <mark data-entity="money">approximately $17.3 million</mark>, or $0.39 per share
for <mark data-entity="date">fiscal 2018</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b>Liquidity
and <mark data-entity="org">Capital Resources</mark> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b>Working
Capital</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: justify"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2019</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt">2018</font></td><td style="padding-bottom: 1pt; font-weight: bold"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 60%; text-align: justify"><font style="font-size: 10pt">Current Assets</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">25,329,373</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">26,052,793</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify; padding-bottom: 1pt"><font style="font-size: 10pt">Current Liabilities</font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">5,039,674</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">3,884,626</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1pt"><font style="font-size: 10pt"><mark data-entity="org">Working Capital</mark></font></td><td style="padding-bottom: 1pt"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">20,289,699</font></td><td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt"> </font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 10pt"> </font></td>
<td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 10pt">$</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 10pt">22,168,167</font></td><td style="padding-bottom: 1pt; text-align: left"><font style="font-size: 10pt"> </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">At September
30, 2019, we had <mark data-entity="money">$22.2 million</mark>.in cash and cash equivalents, a decrease of <mark data-entity="money">$0.7 million</mark>  from <mark data-entity="money">$22.9 million</mark> at September 30, 2018.
The principal reason for this decrease is an increase in operating expenditures incurred in connection with the clinical trials
for <mark data-entity="org">ANAVEX</mark>®sup>®</sup>2-73, as more fully described above.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We intend
to use the majority of our capital resources to advance our clinical trials for <mark data-entity="org">ANAVEX</mark>®sup>®</sup>2-73, and to perform work
necessary to prepare for future development of our pipeline compounds.</font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Cash
Flows</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="white-space: nowrap; text-align: justify; padding-left: 5.4pt"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"><font style="font-size: 10pt">2019</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"><font style="font-size: 10pt">2018</font></td><td style="font-weight: bold"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 70%; text-align: justify; padding-left: 5.4pt"><font style="font-size: 10pt">Cash flows used in operating
    activities</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">(18,527,117</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td><td style="width: 1%"><font style="font-size: 10pt"> </font></td>
<td style="width: 1%; text-align: left"><font style="font-size: 10pt">$</font></td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">(12,582,406</font></td><td style="width: 1%; text-align: left"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify; padding-left: 5.4pt"><font style="font-size: 10pt">Cash flows provided by financing activities</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">17,782,109</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt"> </font></td><td style="text-align: right"><font style="font-size: 10pt">8,072,787</font></td><td style="text-align: left"><font style="font-size: 10pt"> </font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-left: 5.4pt"><font style="font-size: 10pt">Increase (decrease) in cash</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(745,008</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td><td><font style="font-size: 10pt"> </font></td>
<td style="text-align: left"><font style="font-size: 10pt">$</font></td><td style="text-align: right"><font style="font-size: 10pt">(4,509,619</font></td><td style="text-align: left"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Cash
flow used in operating activities</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">There was
an increase in cash used in operating activities of <mark data-entity="money">$5.9 million</mark> during fiscal 2019 as a result of an increase in operating expenditures,
as more fully described above.</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Cash
flow provided by financing activities</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Cash provided
by financing activities for <mark data-entity="date">fiscal 2019 and 2018</mark> were related to cash received from the issuance of shares under the purchase
agreements with Lincoln Park, including <mark data-entity="law">the Purchase Agreement</mark> and a prior purchase agreement with Lincoln Park which has expired
pursuant to its terms (see Note 4 to our Consolidated Financial Statements). During fiscal 2019, we issued <mark data-entity="cardinal">6.7 million</mark> shares
for gross proceeds of <mark data-entity="money">$17.8 million</mark>. During <mark data-entity="date">fiscal 2018</mark>. we issued 2.4 million shares for gross proceeds of <mark data-entity="money">$8.2 million</mark>.</font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Other
Financings</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b>Purchase
Agreement</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">On <mark data-entity="date">June
7, 2019</mark>, we entered into the <mark data-entity="work_of_art">2019 Purchase Agreement</mark> (the  <mark data-entity="work_of_art">2019 Purchase Agreement</mark> ) with <mark data-entity="org">Lincoln Park Capital Fund</mark>, <mark data-entity="org">LLC</mark> (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase <mark data-entity="money">up to $50,000,000</mark> of our common stock.
Concurrently with the execution of the <mark data-entity="work_of_art">2019 Purchase Agreement</mark>  we issued 324,383 shares of our common stock to Lincoln Park as
a fee for its commitment to purchase shares of our common stock under the <mark data-entity="work_of_art">2019 Purchase Agreement</mark> and shall issue up to 162,191
shares pro rata, when and if Lincoln Park purchases, at our discretion, the $50,000,000 aggregate commitment. The purchase shares
that may be sold pursuant to the <mark data-entity="work_of_art">2019 Purchase Agreement</mark> may be sold by us to Lincoln Park at our discretion from time to time
until <mark data-entity="date">July 1, 2022</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 34; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We may direct
Lincoln Park, at our sole discretion, and subject to certain conditions, to purchase <mark data-entity="cardinal">up to 200,000</mark> shares of common stock on any
business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased under certain circumstances
<mark data-entity="cardinal">up to 250,000</mark> shares provided that Lincoln Park’s committed obligation for <mark data-entity="org">Regular Purchases</mark> on any business day shall not
exceed $2,000,000. In the even we purchase the full amount allowed for a Regular Purchase on <mark data-entity="date">any given business day</mark>, we may also
direct Lincoln Park to purchase additional amounts as accelerated and additional purchases. The purchase price of shares of common
stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as
described in <mark data-entity="law">the Purchase Agreement</mark> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">At September
30, 2019, <mark data-entity="money">approximately $45.3 million</mark> in shares of our common stock remained available for purchase by Lincoln Park under the <mark data-entity="work_of_art">2019 Purchase Agreement</mark>  including <mark data-entity="money">$15.4 million</mark> of our shares of common stock currently registered under our effective registration
statement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b>Controlled
Equity Offering Sales Agreement</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">On <mark data-entity="date">July
6, 2018</mark>, the <mark data-entity="org">Company</mark> entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor
Fitzgerald &amp; Co., as agent (“<mark data-entity="work_of_art">Cantor Fitzgerald”</mark>), pursuant to which the <mark data-entity="org">Company</mark> may offer and sell shares
of common stock, for aggregate gross sale proceeds of <mark data-entity="money">up to $50,000,000</mark> from time to time through Cantor Fitzgerald (the “<mark data-entity="work_of_art">At-the-Market
Offering</mark>”). </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Upon delivery
of a placement notice based on the <mark data-entity="org">Company</mark> s instructions and subject to the terms and conditions of <mark data-entity="law">the Sales Agreement</mark>,
Cantor Fitzgerald may sell shares of common stock by methods deemed to be an “at the market offering” offering, in
negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the <mark data-entity="org">Company</mark> 
The <mark data-entity="org">Company</mark> is not obligated to make any sales of shares under <mark data-entity="law">the Sales Agreement</mark>, The <mark data-entity="org">Company</mark> or Cantor Fitzgerald may suspend
or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions.  Cantor Fitzgerald
will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and
applicable state and federal law, rules and regulations and the rules of <mark data-entity="org">Nasdaq</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">The <mark data-entity="org">Company</mark> has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of <mark data-entity="percent">up to 3.0%</mark> of the gross proceeds from the
sale of the Shares pursuant to <mark data-entity="law">the Sales Agreement</mark>,  The <mark data-entity="org">Company</mark> has also agreed to provide Cantor Fitzgerald with customary
indemnification and contribution rights. To date, no shares of common stock have been sold pursuant to <mark data-entity="law">the Sales Agreement</mark>,</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We expect
that we will be able to continue to fund our operations through existing cash on hand and through equity and debt financing in
the future. If we raise additional financing by issuing equity securities, our existing stockholders’ ownership will be
diluted. Obtaining commercial loans, assuming these loans would be available, would increase our liabilities and future cash commitments.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i>Off-Balance
Sheet Arrangements</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b><i> </i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We have
no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to our stockholders.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt; text-transform: uppercase"><b>Application
of Critical Accounting Policies</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Our financial
statements and accompanying notes are prepared in accordance with generally accepted accounting principles in <mark data-entity="gpe">the United States</mark>.
Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets,
liabilities, revenue and expenses. These estimates and assumptions are affected by management’s application of accounting
policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects
of our financial statements is critical to an understanding of our financial statements.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 35; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We base
our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual
results may vary from our estimates due to changes in circumstances, politics, global economics, general business conditions and
other factors. Our significant estimates are related to the valuation of warrants and options.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">There are
accounting policies that we believe are significant to the presentation of our financial statements. The most significant of these
accounting policies relates to the accounting for our research and development expenses and stock-based compensation expense.</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><mark data-entity="org">Research
and Development</mark> Expenses</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the <mark data-entity="org">Company</mark> s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with <mark data-entity="ordinal">third</mark> parties such as contract research organizations (“CROs”), facilities costs, overhead costs and other related
expenses. Milestone payments made by the <mark data-entity="org">Company</mark> to <mark data-entity="ordinal">third</mark> parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with <mark data-entity="org">Accounting Standard Codification</mark> (“<mark data-entity="work_of_art">ASC</mark>”) 730,><mark data-entity="org">Research
and Development</mark>  as these materials have no alternative future use outside of their intended use.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The <mark data-entity="org">Company</mark> makes estimates of costs incurred in relation to external CROs, and clinical site costs. The <mark data-entity="org">Company</mark> analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The <mark data-entity="org">Company</mark> reviews and
accrues <mark data-entity="org">CRO</mark> expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued <mark data-entity="person">CRO</mark> costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording
of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related
to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the
specific clinical study or trial contract.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">In addition,
we incur expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability of
success and length of time to developing commercial applications of the drugs subject to the acquired patents and trademarks is
difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects.
There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties,
we expense the acquisition of patents and trademarks.</font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Stock-based
Compensation</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We account
for all stock-based payments and awards under the fair value-based method.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 36; Value: 1 -->
<div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
<div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">Stock-based
payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees
is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting
period of the award and in the same manner as if we had paid cash instead of paying with or using equity-based instruments. Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based payments
to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date, unless there
is a contractual term for services in which case such compensation would be amortized over the contractual term.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We account
for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded
at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with
a corresponding increase to additional paid in capital.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We use the
<mark data-entity="org">Black-Scholes</mark> option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing
models require the input of highly subjective assumptions, including the expected price volatility. Changes in assumptions can
materially affect the fair value estimate and therefore the
<mark data-entity="org">Black-Scholes</mark> model does not necessarily provide a reliable single
measure of the fair value of our share purchase options.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">For a discussion
of recent accounting pronouncements and their possible effect on our results, see Note 2(n) to our Consolidated Financial Statements
found elsewhere in <mark data-entity="org">this Annual Report</mark> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"> </font></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; font-style: normal"><a name="main_012"></a></section><div id="item_end"></div><div id="edgaug_item7_end"></div></body></html>